In recent years, Eli Lilly has announced a number of increasingly large manufacturing investments. This has led many to wonder what the company will do next. Some of their well-known medications include Trulicity, Jardiance, and Cymbalta.

Organovo’s main drug, FXR314, is going to be tested in a Phase II trial for treating inflammatory bowel disease (IBD). Some common medications for IBD include Mesalamine (Asacol, Pentasa) and Infliximab (Remicade), but FXR314 is being studied to see if it could be a new option.

RedHill will receive an initial payment from Hyloris and could earn up to $60 million based on certain achievements. If applicable, the deal may involve medications like Talicia or Aemcolo.

Idorsia, a pharmaceutical company, couldn’t secure a buyer, so it changed a current partnership and reorganized its financial agreements to get more money.

The Phase III DIAMOND trial successfully achieved its main and additional goals of reducing tics in both children and adults. Some medications involved in such trials might include names like aripiprazole or risperidone, though specific names from this trial aren’t mentioned.

Eikon’s main drug, EIK1001, is currently being tested in a Phase III trial to treat melanoma, a type of skin cancer. It is being used in combination with Keytruda, a medicine developed by the company MSD.

The company’s decision boosts its total investment promises in the U.S. to over $50 billion since 2020. Unfortunately, the text doesn’t provide specific names of pills or medications.

This treatment is for people whose illness got worse after they tried chemotherapy drugs that contain platinum. Some examples of these chemotherapy drugs are cisplatin and carboplatin.

The FDA will decide whether to approve odronextamab, a treatment for relapsed or hard-to-treat follicular lymphoma, by July 30, 2025. If approved, it would join other medications like Rituxan and Gazyva, which are also used to treat this condition.